Stay updated on IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    Minor revision: v3.3.2 replaces v3.2.0; this does not alter any study content or page purpose. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T17:49:38.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The government funding/operating status notice at the top of the page has been removed; core study details and eligibility criteria remain unchanged.
    Difference
    0.3%
    Check dated 2025-11-17T17:33:43.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The updates shown are cosmetic UI/layout changes with no edits to the study's core content (title, NCT ID, interventions, outcomes, or eligibility criteria). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T12:08:39.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    The page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.
    Difference
    3%
    Check dated 2025-10-05T16:44:56.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.
    Difference
    0.1%
    Check dated 2025-09-28T10:00:24.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.0.2 (replacing v3.0.1) and the Back to Top element was removed. No significant changes to core content, pricing, stock, or time slots.
    Difference
    0.2%
    Check dated 2025-09-14T00:15:48.000Z thumbnail image

Stay in the know with updates to IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.